

BY FAX / E-MAIL & CONFIRMATORY COPY BY HAND DELIVERY

June 2, 2014

The Secretary
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,


This is to inform you that the Company has entered into an alliance with Oncobiologics, Inc., USA for the development, manufacture and commercialization of biosimilar monoclonal antibody products. The biologics covered under this alliance are among the most popular therapies in the world for immunology and oncology disease indications.

In this regard, a Press Release is being issued by the Company, a copy whereof is enclosed herewith.

This is for your information and record.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish P Kamath
Corporate Counsel & Company Secretary

Encl: Press Release

Cc: 1) The Secretary
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Ipca Laboratories Ltd.
www.ipca.com

Ipca and Oncobiologics Create Strategic Biosimilars Partnership

Mumbai, India and New Jersey, USA – June 2, 2014— Ipca Laboratories Ltd., India (Ipca) and Oncobiologics, Inc., USA (Oncobiologics) announced today the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products. Under the first part of the agreement, Ipca will in-license and commercialize biosimilar products for the India and associated markets. These products will be developed by Oncobiologics to US FDA and EU regulatory standards for global commercialization. Initial manufacturing will occur in the USA by Oncobiologics and later by Ipca in India. The biologics covered by the agreement are among the most popular therapies in the world for immunology and oncology disease indications. The partnership is planning to launch the first product in 2017.

Under the second part of the agreement, Oncobiologics will replicate its Biologics R&D and Manufacturing facility in India to create a world-class capability for Ipca for further biosimilar commercialization. The Mumbai R&D facility will be designed for development and commercialization of complex monoclonal antibodies. The Manufacturing facility will be located in Vadodara and will utilize the latest single-use manufacturing platform. The R&D facility will be operational from 2015 and the manufacturing facility will be operational by 2016.

"This partnership is an important step toward introducing affordable, high-quality biotherapeutics to India. Ipca is thrilled to partner with Oncobiologics, which brings us excellent biologics development and manufacturing capability, and a deep knowledge of the scientific and quality requirements in the United States," said Chairman and Managing Director of Ipca, Mr. Premchand Godha. "Through this partnership, we look forward to establishing in India a world class biologics operation meeting Indian, US and European Regulatory Standards while leveraging Oncobiologics' ongoing global commercialization for our initial biosimilar pipeline."

"Ipca is one of the leading companies in small-molecule pharmaceuticals in India, with a global footprint. They are distinguished by commercial strength in India and a deep quality culture in their operations, which is essential as we partner to create a strong biologics capability there. Through this partnership we hope to introduce high quality



Ipca Laboratories Ltd.

www.ipca.com

142-AB, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4747 F: +91 22 2868 6954
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837

products developed to stringent western regulatory standards at an affordable cost," commented Oncobiologics Founder & CEO Pankaj Mohan, Ph.D. MBA.

Financial terms were not disclosed.

About Ipca laboratories ltd.

Ipca Laboratories is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to nearly 130 countries now account for nearly 63% of Company's income. Ipca is vertically integrated and produces Finished Dosage Forms and Active Pharmaceutical Ingredients. For more information, please visit www.ipca.com

About Oncobiologics, Inc.

Oncobiologics is a privately-held biopharmaceutical company developing a pipeline of biosimilars and next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 40,000 sq.ft. integrated R&D and Manufacturing facility in Cranbury, NJ. For more information, please visit www.oncobiologics.com

Contact:

Oncobiologics: Rick Gregory
Director of Marketing & Communications
Oncobiologics, Inc.
rickgregory@oncobiologics.com

Ipca: Harish P. Kamath
Corporate Counsel & Company Secretary
Ipca Laboratories Limited
harish.kamath@ipca.com

